» Articles » PMID: 16697315

Renal Impairment and Outcomes in Heart Failure: Systematic Review and Meta-analysis

Overview
Date 2006 May 16
PMID 16697315
Citations 274
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: We estimated the prevalence of renal impairment in heart failure (HF) patients and the magnitude of associated mortality risk using a systematic review of published studies.

Background: Renal impairment in HF patients is associated with excess mortality, although precise risk estimates are unclear.

Methods: A systematic search of MEDLINE (through May 2005) identified 16 studies characterizing the association between renal impairment and mortality in 80,098 hospitalized and non-hospitalized HF patients. All-cause mortality risks associated with any renal impairment (creatinine >1.0 mg/dl, creatinine clearance [CrCl] or estimated glomerular filtration rate [eGFR] <90 ml/min, or cystatin-C >1.03 mg/dl) and moderate to severe impairment (creatinine > or =1.5, CrCl or eGFR <53, or cystatin-C > or =1.56) were estimated using fixed-effects meta-analysis.

Results: A total of 63% of patients had any renal impairment, and 29% had moderate to severe impairment. After follow-up > or =1 year, 38% of patients with any renal impairment and 51% with moderate to severe impairment died versus 24% without impairment. Adjusted all-cause mortality was increased for patients with any impairment (hazard ratio [HR] = 1.56; 95% confidence interval [CI] 1.53 to 1.60, p < 0.001) and moderate to severe impairment (HR = 2.31; 95% CI 2.18 to 2.44, p < 0.001). Mortality worsened incrementally across the range of renal function, with 15% (95% CI 14% to 17%) increased risk for every 0.5 mg/dl increase in creatinine and 7% (95% CI 4% to 10%) increased risk for every 10 ml/min decrease in eGFR.

Conclusions: Renal impairment is common among HF patients and confers excess mortality. Renal function should be considered in risk stratification and evaluation of therapeutic strategies for HF patients.

Citing Articles

Heart Failure and Worsening Renal Function: Prevalence, Risk Factors, and Impact on Hospital Readmissions in an Urban Minority Population.

AlShammari A, Magdits M, Majdalani R, Devarajan S, Hughes A, McCann L J Clin Med. 2025; 14(3).

PMID: 39941548 PMC: 11818860. DOI: 10.3390/jcm14030877.


Clinical features and prognostic factors of cardiorenal anemia syndrome in China: a retrospective single-center study.

Zhu M, Liu M, Lu C, He D, Li J, Xu X BMC Cardiovasc Disord. 2024; 24(1):761.

PMID: 39736509 PMC: 11686829. DOI: 10.1186/s12872-024-04452-3.


Connecting intermediate phenotypes to disease using multi-omics in heart failure.

Moore A, Venkatesh R, Levin M, Damrauer S, Reza N, Cappola T Pac Symp Biocomput. 2024; 30:504-521.

PMID: 39670392 PMC: 11822568.


Current Review of Heart Failure-Related Risk and Prognostic Factors.

Wilk M, Wilk J, Urban S, Gajewski P Biomedicines. 2024; 12(11).

PMID: 39595125 PMC: 11592058. DOI: 10.3390/biomedicines12112560.


Evaluating the safety and effectiveness of tolvaptan in patients with heart failure and renal impairment: a systematic review and meta-analysis.

Kumar A, Iqbal U, Amin S, Arsal S, Ali S, Shafique M Eur J Clin Pharmacol. 2024; 81(2):203-216.

PMID: 39579178 DOI: 10.1007/s00228-024-03778-3.